Table 1.
Clinicopathologic characteristics of EOC patients
| Variable | Total number % | |
|---|---|---|
| Age median (range) |
52 (22–73) |
|
| < 50 |
43 |
41 |
| ≥ 50 |
61 |
59 |
| FIGO stage |
|
|
| I |
20 |
19 |
| II |
16 |
16 |
| III |
50 |
48 |
| IV |
18 |
17 |
| Histological grade |
|
|
| G1 |
10 |
10 |
| G2 |
14 |
13 |
| G3 |
80 |
77 |
| Lymph nodal involvement |
|
|
| Positive |
40 |
38 |
| Negative |
64 |
62 |
| Residual tumor size |
|
|
| 0 mm |
76 |
75 |
| 0–10 mm |
28 |
25 |
| CA125 serum level median (range) |
263 (19–8410) |
|
| ≤ 35 U/ml |
7 |
7 |
| > 35 U/ml |
97 |
93 |
| ER expression |
|
|
| Positive |
58 |
56 |
| Negative |
46 |
44 |
| PR expression |
|
|
| Positive |
47 |
45 |
| Negative |
57 |
55 |
| Her1 expression |
|
|
| Positive |
37 |
36 |
| Negative |
67 |
64 |
| Her2 expression |
|
|
| Positive |
51 |
49 |
| Negative |
53 |
51 |
| P53 expression |
|
|
| Positive |
73 |
70 |
| Negative | 31 | 30 |